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Abstract We describe here a minimally invasive glucose bio-
sensor based on a microneedle array electrode fabricated from
an epoxy-based negative photoresist (SU8 50) and designed
for continuous measurement in the dermal compartment with
minimal pain. These minimally invasive, continuous monitor-
ing sensor devices (MICoMS) were produced by casting the
structures in SU8 50, crosslinking and then metallising them
with platinum or silver to obtain the working and reference
electrodes, respectively. The metallised microneedle array
electrodes were subsequently functionalised by entrapping
glucose oxidase in electropolymerised polyphenol (PP) film.
Sensor performance in vitro showed that glucose concentra-
tions down to 0.5 mM could be measured with a response
times (T90) of 15 s. The effect of sterilisation by Co60 irradi-
ation was evaluated. In preparation for further clinical studies,
these sensors were tested in vivo in a healthy volunteer for a
period of 3–6 h. The sensor currents were compared against
point measurements obtained with a commercial capillary
blood glucometer. The epoxy MICoMS devices showed cur-
rents values that could be correlated with these.
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Abbreviations
CGM Continuous glucose monitoring
ISF Interstitial fluid
MICoMS Minimally invasive continuous
monitoring sensors
T1D Type 1 diabetes
Introduction
First approved by the FDA for the management of diabetes
in 1999, continuous glucose monitoring (CGM) technology
has now emerged as an important diagnostic tool for detect-
ing episodes of high blood glucose (hyperglycaemia) and
low blood glucose (hypoglycaemia). The real time informa-
tion on changes in glucose concentrations in terms of the
direction, duration and magnitude provided by CGM devices
improves glycaemic control as assessed by a reduction in the
levels of glycated haemoglobin (HbA1c) [1]. There are re-
ports that suggest that CGM is also associated with reduc-
tion in episodes of hypoglycaemia in both children and
adults with type 1 diabetes1. The advantages of regular use
of CGM have been quantified; for instance, for every 1-day
increase in sensor usage per week, an average HbA1c re-
duction of 0.15 % is observed [2, 3]. However, despite the
clear benefits of continuous glucose monitoring, it has not
been widely implemented in the routine management of type
1 diabetes (T1D) due to several major challenges. This is
evident from T1D exchange data demonstrating that CGM
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technology is being used by only 6.5 % of people with type
1 diabetes in the USA (even with reimbursement), and that
among those individuals who have used a CGM, two thirds
subsequently stopped using it [4–6]. The major disadvan-
tages associated with the commercially available CGM de-
vices are their invasiveness and the associated discomfort,
negatively affecting adherence and the subsequent effective-
ness of CGM. Data on CGM sensor accuracy have shown
clinically significant, reduced accuracy in the critical
hypoglycaemic range representing another important barrier
to use with a high frequency of false hypoglycaemia alarms
[7]. Finally, variable reimbursement for existing CGM sys-
tems limits access and high costs limit self-funding oppor-
tunities for people with diabetes [8]. We have sought to
address these limitations through the development of a novel
electrochemical sensor based on microneedle array elec-
trodes (MICoMS) for CGM. Earlier, we reported on the
use of microneedle structures functionalised with GOx, a
TTF mediator and an epoxy PU membrane for the measure-
ment of glucose in vitro [9, 10]. However, these were un-
suited for in vivo use and hence this paper describes the
development of minimally invasive, continuous monitoring
sensors (MICoMS) suitable for measurement in the dermal
interstitial fluid.
Fabrication of microneedles for transdermal drug and
vaccine delivery has been reported extensively in the
literature [11–16]. The microneedle array electrochemi-
cal sensors reported here have the potential for mass
production by techniques such as injection moulding
and hot embossing and thus lowering costs so they need
be used for only short periods (24–48 h) before replace-
ment. This should minimise problems associated with
long-term implantation.
Some of the approved commercial devices for continu-
ous glucose monitoring include Enlite (Medtronic), G5
(Dexcom) and the FreeStyle Libre (Abbott). Compared to
the conventional subcutaneous microneedle-based sensors,
the MICoMs demonstrated in this paper offer following
major advantages: (1) By virtue of their dimensions, they
are minimally invasive and can be easily inserted and
regularly replaced as compared to subcutaneous devices,
which require implantation using an applicator. (2)
Sampling mainly in the dermal space (Fig. 1) will lead
to reduced biofouling effects [17]. (3) It provides a larger
electrode surface area and thus larger currents (>100 nA)
than other subcutaneously implanted sensors (>10 nA). (4)
The microneedle arrays electrodes (MICoMS) can be mod-
ified and distributed into working electrodes and reference
electrode facilitating multiplexing or single analyte sensing
by multiple MICoMSs. The continuous glucose biosensors
described here are first generation glucose sensors made of
platinum functionalised by glucose oxidase with
electropolymerised phenols.
Materials and methods
Materials
SU-8 photoresist was obtained from Chestech Ltd, UK.
Ferrocene carboxylic acid (FCA), phenol was obtained from
Sigma-Aldrich, UK. Glucose oxidase (Glucose Oxidase
HPS300, Activity 239 U/mg powder @25oC, source Ex
Aspergillus niger) was procured from Sekisui Diagnostics
(UK), Ltd. For the in vivo studies comparison, an ACCU-
CHEK Aviva blood glucose system was used for intermittent
capillary blood.
Fabrication of the microneedle array glucose sensor
Aluminium masters, fabricated using an electrical discharge
machining (EDM) technique, were used to create moulds of
polydimethoxy siloxane (PDMS). The PDMS moulds were
subsequently used to cast SU8 50 using vacuum and spinning.
The SU8 50 cast PDMS moulds were subjected to 10 mmHg
vacuum pressure for 2 min and spun in petri dish at 4000 rpm
for 30 min in a centrifuge (Eppendorf). SU8 50 was then
cross-linked by exposure to UV light at 365 nm for 30 min.
The final epoxy MICoMSs were then obtained by peeling off
from the PDMS layer (Fig. 2). Using the casting moulding
Fig. 1 Showing the two different approaches (microneedle array
electrodes versus commercial CGM) and the two regions of the skin
compartment used to access the interstitial fluid
Fig. 2 Fabrication procedure of microneedle array electrode. a
Aluminium master of microneedle array made by EDM; b PDMS
mould obtained from the aluminium master; c bare microneedle array
electrodes with one reference and three working electrode arrays
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technique, >80 epoxy microneedle arrays can be fabricated
per week.
Characterisation of microneedle devices using scanning
electron microscopy (SEM)
The microneedle array electrode (MICoMS)-based continu-
ous glucose sensor consists of a three-dimensional out-of-
plane microneedle array, with 64 microneedles perpendicular
to the base plate and arranged as four 4 × 4 arrays. The
microneedle array electrode-based devices were characterised
using a JEOL 5610 SEM. Attempts to imaging the SU8 50
microneedles in vivo using OCT were unsuccessful due to
high absorbance of the material and therefore optically trans-
parent polycarbonate structures were used instead.
Metallisation, modification of microstructure region
and wire bonding to device
One of the microneedle array was masked with a tape and the
remaining three coated with an adhesion layer of titanium
(15 nm) followed by a platinum layer (50 nm) by conformal
sputtering (DC sputter system, JLS MPS 500) in a clean room
to produce three electrodes. In the next step, these three elec-
trodes are masked and the remaining region metallised with
silver (100 nm). In this work, the three platinum microneedle
array electrodes are used as working electrodes and the fourth,
metallised with silver, was treated with a saturated FeCl3 so-
lution to obtain a Ag/AgCl reference electrode. The potential
of the integrated reference electrode was measured against an
external reference electrode and found to be higher by 30 ±
4 mV.
One millimetre holes were drilled at the periphery of the
metallised part of microneedle structures, using a bench top
drill. Wire bonding was done using a wrap equipment wire
(RS Pro Black, Kynar Wire Wrap Equipment Wire, 0.05 mm2
CSA, 300 V 0.4 A, 50 m) run through the holes and held in
place by silver conductive, adhesive paint (RS Silver Bottle
Paint Conductive Adhesive) and ATACS5104 (Sigma) epoxy
adhesive.
The electrode surface of the microneedle array was
a s s e s s ed by cyc l i c vo l t amme t r y (CV) u s i ng
ferrocenecarboxylic acid (FCA) as a redox probe. In
addition, cyclic voltammetry and chronoamperometry
were performed to model the behaviour of the
microneedle array electrode.
Functionalisation of the microneedle array electrode
by electropolymerisation
The glucose biosensors described here were functionalised
with an enzyme film using an electropolymerisation method
described earlier [1]. For the electropolymerised polyphenol,
the electrode was placed in a 50 mM solution of phenol and
10 mg/mL of GOx enzyme dissolved in 100 mM PBS. The
pH of the solution was buffered to pH 7.2. Each cycle com-
prised of holding the working electrode at 0 V for 20 s,
polarising it to a potential of 0.9 V for 15 min for
electropolymerisation of the film. Each cycle was repeated
six times to obtain the desired film thickness and glucose
oxidase loading. Following electropolymerisation, the biosen-
sor was gently rinsed with de-ionised water and stored dry
overnight at 4 °C before use.
Evaluation of GOx functionalised microneedle arrays
Dose–response curves of functionalised microneedle array
electrodes
Electrochemical measurements were performed in a two-
electrode configuration with CHI 1030b potentiostat (CHI
Instruments) running general-purpose electrochemical soft-
ware (GPES v4). To make maximum use of the platinum
microneedle arrays as working electrodes, a two electrode
was used. With the currents passed, there is no evidence
to suggest that RE has changed its performance.
Two hundred microliters aliquots of varying glucose
concentrations prepared in 100 mM PBS solution
(pH 7.2) were added stepwise to the devices with the
microneedle electrode arrays polarised at 0.7 V against the
monolithically integrated Ag/AgCl counter/reference elec-
trode. The steady-state current measured at 60 s was deter-
mined as a function of the glucose concentration over the
range 0 to 30 mM. The apparent Imax and Km were found
by plotting from the current at 60 s against concentration
and fitting the points with the Michealis-Menten equation
fitting in OriginPro 9.0. The Michealis-Menten equation is
given as:
I ¼ Imax S½ =Km þ S½ 
where Imax is the maximum current, [S] is the glucose
concentration and Km is the Michaelis constant for glucose
oxidase.
Chemical crosstalk studies
There is a possible complicating factor in any sensor array
based on the detection of diffusible species. If the sensors
are too close together, hydrogen peroxide generated on one
electrode diffuses to another. To confirm the absence of sensor
‘chemical crosstalk’, one set of the microneedle electrodes
was functionalised with glucose oxidase as described above.
The other two-microneedle sets of electrodes on the same
device were not functionalised.
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Dose–response curves post sterilisation of functionalised
microneedle array electrodes
The microneedle arrays were subjected to 25 kGy of
Co60 (Synergy Health) for assay of the bio burden
levels on the microneedle arrays and subsequent estima-
tion of dose for sterilisation. These studies were done in
accordance with ISO 11137-2:2012, Sterilisation of
Health Care Products-Radiation-Part2: Establishing the
Sterilisation dose.
In vivo studies using the microneedle array
electrodes-based glucose biosensors
Sterilised microneedle array electrode-based glucose bio-
sensors were inserted into the forearm of a healthy vol-
unteer and their glucose concentration measured every
15 min using a finger stick glucometer. A CHI
potentiostat was used to continuously bias the inserted
microneedle array working electrodes at 0.7 V against
the integrated counter/reference electrode with a data
point being collected every 60 s. The in vivo studies
were made on two separate occasions each lasting 3–
6 h.
For the in vivo studies in consented healthy volun-
teer, approvals were obtained from the research ethics
committee (REC reference: 16/LO/0007, IRAS project
ID 190530).
Results and discussion
SEM characterisation of base microneedle array
structures
SEM images of the base microneedle arrays at different
magnifications and tilt angles revealed the dimensions of
each microneedle. The microneedles were ≈1000 μm in
length with a base of 600 μm, a tip diameter of 35 μm
and pitch of 1200 μm (tip-to-tip distance). OCT image
obtained after insertion of the sterilised, uncoated
microneedle fabricated from polycarbonate material is
shown below in Fig. 3(d).
Modelling the electrochemical behaviour of microneedle
array electrodes
Since there is no cited work on the diffusion profile of pyra-
midal microneedle array electrodes, the microneedle array
electrode was electrochemically characterised with a simple
assumption. It was assumed that each 4 × 4 microneedle array
behaves as a planar electrode. The diffusion current for a
planar electrode in a chronoamperometry measurement is de-
scribed in Cottrell equation below:
id tð Þ ¼ nFADoC*o= πDotð Þ1=2
where A is the area of the electrode, F = Faraday’s constant
(96,485 C mol−1), Do the diffusion coefficient of ferrocene
a b
c d
Fig. 3 Showing SEM and OCT
image(s) of the bare
microneedles. 3(a), Top image
showing the micrographs at ×35
magnification; 3(b), (c) showing
SEM micrographs obtained after
tilting the sample stage at 60° and
at ×25 and ×100. 3(d) shows an
OCT image of a transparent
microneedle of similar geometry
in a healthy volunteer
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carboxylic acid (5.7 × 10–6 cm2 s−1), n the number of elec-
tron(s) involved (n = 1), t time in seconds and C*o the con-
centration of ferrocene carboxylic acid (5 mM).
The area of the microneedle array was evaluated by
chronoamperometry and the details of the steps are described
as following. Cyclic voltammetry with 5 mM ferrocene car-
boxylic acid redox probe was performed to find the peak po-
tential EP (forward) which was 0.38 V (Fig. 4). After applying
a potential of 0.50 V (EP) to the electrode with 200 μL of the
5 mM ferrocene carboxylic acid, the current was measured for
120 s (Fig. 4b).
Most of the current decays within the first 10 s and this
current, id, was plotted against t
-1/2, as shown in Fig. 4c, with
the slope nFADoC
*
o / (πDo)
1/2. At short period of time, the
Cottrell term nFADoC
*
o / (πDo)
1/2 dominates, and for longer
period of time, it is anticipated that other factors such as con-
vection come into play.
As seen from Fig. 4b, inset, fitted current values are higher
than the experimental values at shorter time and lower at lon-
ger time. This discrepancy (approx. 3 %) is maintained
throughout the later part of the 120-s measurements. At longer
times, the noise is significantly lower than one would expect
for a simple planar electrode. It appears that the microneedle
structures may act as pillars and so stabilise the current.
The area of equivalent microneedle array electrodes (WE1,
2 and 3) were calculated from the slope of the Cottrell plot
(Fig. 4c). The area of the microneedle array electrode calcu-
lated using the Cottrell equation, for WE1, 2 and 3 were 0.32,
0.28 and 0.31 cm2, respectively, which is in close agreement
to the value calculated geometrically (0.38 cm2) (Table 1). The
area of each microneedle array was calculated using the fol-
lowing values: area of microneedle array (0.5 × 0.5) cm2, sur-
face area of 16 pyramidal microneedles (each with base
0.06 cm, height 0.1 cm).
These studies provide valuable insight on the behaviour of
the microneedle array electrodes in context to devices for con-
tinuous glucose sensing in the interstitial fluid. As seen from
the OCT images with polycarbonate microneedles (penetra-
tion depth 800 μm), we anticipate that 80 % of the
microneedle array length (from the tip) will be in contact with
the ISF and the mass transport will be mainly driven by dif-
fusion of the glucose to the sensor surface.
Evaluation of GOx functionalised microneedle array
electrodes
Dose–response curves of microneedle array electrodes
functionalised by phenol electropolymerisation
The electropolymerised devices were tested with various glu-
cose concentrations using chronoamperometry (Fig. 5).
From the chronoamperometry studies, the dose–response
curves were obtained from filling to the Michealis-Menten
equation. It is observed that glucose concentration as low as
0.5 mM could be easily measured. The average 90% response
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Fig. 4 a Cyclic voltammetry of 200 μL of 5 mM FCA at a scan rate of
100 mV s−1. The artefacts (dotted circles) at V < 0.1 V seen for WE1 is
due to epoxy used for wire bonding. bChronoamperometry measurement
with 200 μL of 5 mM ferrocene carboxylic acid with the inset showing
the fitted data. c: I v/s t−1/2 plot obtained from chronoamperometry
measurement with 200 μL of 5 mM ferrocene carboxylic acid
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time T90 was approximately 15 ± 2 s. The responsiveness, R,
of each sensor was also calculated with equation below,
R ¼ I10mM−I1mM=9
where I10mM and I1mM were the steady-state currents at glu-
cose concentration of 10 and 1 mM, respectively.
In total six devices were fabricated and the average Km
values for all the sensor readings (n = 50) was 9.87 +
1.62mM.Variations inKm value between the devices were seen
to be larger than that between the sensors within a device. The
devices showed variability in the Imax between the MICoMS
electrodes. The plausible reasons for this variation between the
electrodes in the same device are factors such as differences in
area of the MICoMS electrodes, distance of the working elec-
trode from the reference electrode yielding variable IR drops
and the total enzyme loading during electropolymerisation.
The variations in the area of the MICoMS electrodes are
probably introduced during the masking step. In general, it is
found that two of the electrodes give more similar current
response compared to the third and this appears to correlate
with the distance from the integrated reference electrode.
Herein, two electrodes that agree are equidistant and the out-
lier slightly further away. Finally, the It curves obtained from
the electro polymerisation of phenol to yield polyphenol films
entrapped with GOx enzyme are different for the three
MICoMS electrodes suggesting differences in enzyme
loading. Normalisation of the current values with the total
charge obtained from the It curves from electropolymerisation
reduces the variation between the microneedle arrays.
Chemical crosstalk studies
To confirm the absence of sensor ‘chemical crosstalk’, one of
the microneedle electrodes was functionalised with glucose
oxidase as described above. The other two were left
unfunctionalised. As seen in Fig. 6, no crosstalk between the
microneedle electrodes is observed.
Comparison of pre- and post sterilisation dose–response
curves of functionalised microneedle array electrodes
There are reports in the literature suggesting that sterilisation
of glucose biosensors with gamma irradiation from 25 to
35 kGy adversely affect performance [18]. Dose–response
curves post sterilisation was obtained using method described
above. A comparison of pre and post sterilisation is shown in
Fig. 7. As seen from the dose–response curves, the Imax values
decrease post sterilisation as might be expected if there was
lesser enzyme activity.
Table 1 Intercept and slope
obtained from the Cottrell plots
for microneedle array electrodes
Electrode Intercept Slope Statistics Area of electrode (in cm2)
(Amperes) (Amperes) Adj. R-square Experimentally Geometrically
WE1 1.075E−05 + 0.027 2.10E−04 + 0.013 0.99559 0.32 0.38
WE2 1.49E−05 + 0.034 1.85E−04 + 0.016 0.99109 0.28 0.38
WE3 1.075E−05 + 0.05 2.05E−04 + 0.024 0.98378 0.31 0.38
Values are ± standard error
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Fig. 5 Dose–response curves obtained for two devices functionalised
with polyphenol films entrapped with glucose oxidase. Data is current
values at 60 s minus background current
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Fig. 6 Dose–response curves obtained after functionalisation of a single
working electrode (WE1—black squares) with glucose oxidase
(Km = 4.6 ± 2.29 mM, Imax = 180 ± 4 μA). WE2 (blue triangles) and
WE3 (red circles) are blank electrodes
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Initial in vivo studies with the microneedle array
electrodes-based glucose biosensors
Studies over short time periods (ranging from 3 to 6 h) were
done using sterilised microneedle array devices. These short-
term studies were undertaken for the convenience of the vol-
unteer as it involved mobilising next to the potentiostat setup.
We anticipate that these studies will provide valuable feed-
back on the sensor and the supporting setup that will enable
development of portable bio-instrumentation around the sen-
sor for longer time measurements.
Unprocessed data from our initial in vivo sensing after
insertion of the device into the forearm of a healthy volunteer
is presented here. As seen in Fig. 8, the sensors are measuring
an output current from the skin ISF over 3–6 h. In both in-
stances, it is evident that the sensor takes about an hour to
reach a stable baseline. This could be the time required for
the polyphenol films entrapped with the GOx enzyme to
equilibrate with the environment within the dermal ISF.
Many commercially available devices too have an equilibra-
tion time and therefore are recommended to be implanted a
few hours before recording the glucose measurements [19].
As seen in Fig. 8a, the sensor shows an increased current
value of 4500 nA in response to a glucose bolus (slice of cake
in this instance) over duration of 45min and drops back down.
There is some correlation and time lag between the capillary
blood and the dermal ISF (Fig. 8a, b). Whilst the dimensions
are designed to obtain a minimally invasive sensor, it is evi-
dent from these in vivo studies that major operational chal-
lenge is to keep the sensors fixed in the sub-dermal space. As
observed in Fig. 8b, artefacts can be seen due to movement of
the arm. It is worth noting that the duration of these is much
shorter than the duration of changes in glucose concentration.
There are various algorithmic approaches establishing the
relationship between the measured current and glucose con-
centration; however, that is beyond the scope of this paper.
For purposes of demonstrating the device function, we have
presented unprocessed data. The sensor will be further
optimised for in vivo measurements through clinical studies
in healthy volunteers and subjects with T1D. For the clinical
assessments, we will use the YSI measurements of venous
blood, a gold standard, for the optimisation of the devices.
In real life scenario, we anticipate the use of capillary blood
measurements as means for calibration continuous glucose
monitoring sensors.
The ability to constantly and accurately monitor blood glu-
cose levels with a discrete device represents the top research
priority for people with type 1 diabetes and specialist clini-
cians [20]. One of the major barriers to achieving these prior-
ities is sensor accuracy [21]. Reduced sensor accuracy of
existing electrochemical continuous glucose sensors is partic-
ularly evident in the hypoglycaemic range, resulting in either
missed episode of hypoglycaemia or false hypoglycaemic
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Fig. 7 Dose–response curves for devices, pre and post sterilisation. As
seen here, the Im values drop
Fig. 8 In vivo data obtained on two different days with two different
devices after inserting the microneedle array electrodes on the forearm
and biased at 0.7 V versus integrated Ag/AgCl reference electrode,
plotted against finger stick (measurements represented as star sign);
inset, showing the location on forearm where the devices were inserted
for in vivo studies. a and b show in vivo measurements done over 3 h
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alarms with subsequent reduced sensor reliability and patient
satisfaction [22].
In recent years, there has been increasing interest in the use
of microneedle technology for transdermal drug delivery [23]
and for sensing of ISF analytes [24]. By virtue of their mini-
mally invasive nature, use of microneedle arrays is associated
with no or minimal pain, no bleeding, minimal skin reaction,
rapid skin recovery and a reduced infection risk. Moreover,
they provide the potential to improve sensor accuracy by pro-
viding a large surface area for the electrochemical reaction
providing the potential to improve the signal/noise ratio with
subsequent improvement in device sensitivity and accuracy.
The use of multiple simultaneous glucose sensors im-
proves accuracy and precision of continuous glucose moni-
toring [25]. Partitioning the microneedle array into four in-
dividual 4 × 4 sub-arrays provides redundancy for technical
failure of single sensors as a single malfunctioning sensor
can be voted out on the basis of divergent results using
conventional voting protocols.
Conclusion
We have demonstrated that microneedle sensors reproducibly
responded to changing glucose concentrations with linear re-
sponses seen in the physiological range (0–30 mM). There
was also no crosstalk between the microneedle arrays, which
indicates the effectiveness of redundancy of these devices for
single analyte measurement or multiplexed measurement of
analytes.
Sterilisation of the microneedle devices by gamma ray ir-
radiation did reduce the response of the device but that the
devices still perform adequately, post sterilisation. The
sterilised devices were stable over several days of storage at
ambient conditions. The in vivo studies in human volunteer
yielding measurable currents and correlation to the capillary
bloodmeasurements are important observations in preparation
for clinical studies to assess safety, efficacy and correlation of
the current values with that of the glucose concentration in the
ISF in human subjects.
Continuous glucose monitoring technology has emerged as
an important tool for management of people with diabetes.
However, widespread use of this technology can only be
achieved if the CGM devices become more accurate, reliable,
less invasive and cost-effective.
In this paper, we describe fabrication and evaluation of a
novel glucose sensor based on microneedle technology. This
sensor performs electrochemically post sterilisation and can
measure current in vivo when inserted in the forearm. This
robust innovation has the potential to address some of the
important challenges facing existing CGM devices including
invasiveness, pain, accuracy and cost.
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